Related Experiment Videos
Beta blockade early in acute myocardial infarction.
The American Journal of Cardiology
|July 15, 1987
Summary
Early intravenous beta blockers significantly reduce mortality in acute myocardial infarction patients, especially when administered within two hours of symptom onset. This treatment is safe, effective, and cost-effective.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Intravenous beta blockers show promise in reducing complications of acute myocardial infarction (AMI).
- Previous studies, including ISIS-1, indicated a potential mortality benefit with intravenous beta blockade, though with wide confidence intervals.
Purpose of the Study:
- To assess and compare the effects of early intravenous atenolol versus control treatment on mortality in patients with AMI.
- To evaluate the safety and cost-effectiveness of early intravenous beta blockade in AMI.
Main Methods:
- A large-scale randomized controlled trial involving 16,027 patients with AMI.
- Patients received either early intravenous atenolol or control treatment.
- Primary endpoint was vascular death, with follow-up at 1 week and 1 year.
Main Results:
- A significant 15% decrease in mortality was observed, primarily within the first 24-36 hours.
- Mortality at 1 week (313 vs. 365 deaths) and 1 year favored the atenolol group.
- Treatment initiated within 2 hours of pain onset showed a highly significant mortality reduction.
- Excess inotrope use (1-2%) and emergence of heart block were noted as potential concerns.
Conclusions:
- Early intravenous beta blockade is a safe and effective strategy for managing acute myocardial infarction.
- The benefits are most pronounced when treatment is initiated rapidly.
- This approach is considered cost-effective compared to oral beta blockade post-discharge.